abrdn Physical Palladium Shares ETF vs Tempus AI — how do they compare? abrdn Physical Palladium Shares ETF trades at $21.05 (market cap $586.03M), while Tempus AI trades at $70 (market cap $12.77B). The key difference: Tempus AI is far larger — about 21.8× abrdn Physical Palladium Shares ETF's market cap, and Tempus AI is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold abrdn Physical Palladium Shares ETF for 33 Days and Tempus AI for 22 Days on average.
| PALL | TEM | |
|---|---|---|
Market Cap | $586.03M | $12.77B |
Volume | 1,073,971 | 8,980,490 |
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $37.18 | $99.28 |
52-Week Low | $20.30 | $41.55 |
Typical Hold Time | 33 Days | 22 Days |
Enterprise Value | — | $13.40B |
Signals from Pluang's Aura AI — not financial advice
PALL (Aberdeen Physical Palladium Shares ETF) trades at $20.30, down 4.47% with bearish technical signals from moving averages but bullish RSI readings. The ETF tracks palladium prices, which have declined 47% from January 2026 highs. Recent news highlights palladium's underperformance versus gold and silver, with some analysts viewing current levels as a buying opportunity given supply risks and industrial demand.
PALL presents a contrarian opportunity as palladium approaches technical support levels, though the metal faces headwinds from automotive sector volatility. The ETF's value depends entirely on palladium price movements rather than company fundamentals, creating pure commodity exposure with significant price volatility risk.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →